Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Stomach cancer rates in the United States have been steadily decreasing for decades, but recent trends reveal an increase in early-onset stomach cancer in people younger than 50, particularly women.

Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

The authors note that the evidence is insufficient for making a recommendation on upper endoscopic screening for gastric cancer (GC)/GPMC detection in US populations deemed high risk for GC.

The first barrier Grivas notes is limited infusion room capacity and the need for rapid chair turnover. Other external barriers for patients include transportation and lodging. Grivas highlights that ...

et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol 16, 57 (2023). [6] Jin Li et al., HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive ...

the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer. According to the U.S. FDA, the drug or biological product receives an ODD will be eligible for ...